Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ACADIA Pharmaceuticals Inc. ACAD

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
3.40
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 3 — — 1 5 2 3 1 1 1 —
Insider Ownership
0.91%

Capital & Financial Ratios

Market Cap
4,730.00
Revenue
1,138.64
Net Income
380.48
Free Cash Flow
145.63
Net Debt
(956.47)
Current Ratio
3.39
Debt/Equity
0.00
P/E ratio
12.13
P/S ratio
4.11
P/B ratio
3.58
Past 5Y EPS Growth
28.03%
This Y EPS Growth
(73.12%)
Next Y EPS Growth
48.14%
Next 5Y EPS Growth
(11.92%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2026 ‡‡‡‡
2025 ‡‡‡‡
2024 ‡‡‡
2023 ‡‡‡‡
2022 ‡‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 438.87 755.99 819.69 956.47
Receivables 102.35 104.70 148.23 166.33
Inventory 35.82 21.95 34.67 32.37
Other — — — —
616.13 938.32 1,062.11 1,224.55
2023 2024 2025 Q'26
Payables 17.54 16.19 10.90 44.57
ST’ Debt — — — —
Other — — — —
254.25 394.87 277.11 361.44
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 268.06 307.96 — —
—
’25 244.32 264.57 278.63 283.99
1,071.51
’24 205.83 241.96 250.40 259.60
957.80
’23 118.46 165.24 211.70 231.04
726.44
’22 115.47 134.56 130.71 136.49
517.24
’21 106.55 115.22 131.61 130.76
484.15
’20 90.07 110.10 120.58 121.01
441.76
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 33.98 100.78 — —
—
’25 20.32 63.96 74.29 (48.73)
109.84
’24 29.08 25.01 63.25 40.38
157.72
’23 (17.93) 8.20 (58.95) 85.39
16.70
’22 (76.33) (13.12) (0.73) (23.85)
(114.03)
’21 (60.15) (25.33) (17.06) (23.12)
(125.66)
’20 (49.00) (36.88) (22.79) (27.49)
(136.17)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 28.77 95.69 — —
—
’25 (78.51) 63.66 (24.94) (52.74)
105.15
’24 29.08 25.01 63.18 39.93
157.20
’23 (17.93) (31.80) (59.00) 85.39
(23.35)
’22 (76.33) (13.12) (0.73) (23.85)
(114.03)
’21 (61.22) (25.37) (17.06) (23.12)
(126.78)
’20 (49.94) (39.82) (24.51) (29.49)
(143.75)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.02 0.18 — —
—
’25 0.11 0.16 0.42 1.60
2.30
’24 0.10 0.20 0.20 0.86
1.36
’23 (0.27) 0.01 (0.40) 0.28
(0.37)
’22 (0.70) (0.21) (0.17) (0.26)
(1.34)
’21 (0.42) (0.27) (0.09) (0.27)
(1.05)
’20 (0.57) (0.27) (0.54) (0.42)
(1.79)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.7
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.24 15.77 14.15 13.40 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.06 33.99 31.82 28.35 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 513 598 654 798 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.01 1.21 1.46 1.34 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 517.24 726.44 957.80 1,071.51 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 98.03% 94.27% 91.46% 91.69% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (213.44) (51.04) 258.08 138.90 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.27%) (7.03%) 26.94% 12.96% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (215.97) (61.29) 226.45 391.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.71) (1.98) 6.58 6.34 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.20 4.43 5.78 6.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.34) (0.37) 1.37 2.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.71) 0.10 0.95 0.65 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 (0.24) 0.00 (0.03) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.71) (0.14) 0.95 0.62 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.48 2.64 4.42 7.29 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 161.68 163.82 165.72 168.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 13.49 11.51 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.10 6.96 3.17 4.20 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.59 11.71 4.15 3.66 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.42 6.43 2.45 3.49 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.83) (200.17) 19.99 (40.16) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (114.03) 16.70 157.72 109.84 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — (40.05) (0.52) (4.69) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (114.03) (23.35) 157.20 105.15 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 382.31 361.87 543.45 785.00 — — —
Working Cap'
‡‡‡‡‡ — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.00 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (354.82) (438.86) (755.99) (819.69) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 400.41 431.76 732.79 1,227.39 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.54%) (9.17%) 23.39% 28.42% ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (306.53%) 0.00% 0.00% 16.07% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.89%) (14.73%) 38.89% 39.89% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Acadia Pharmaceuticals (ACAD) exemplifies a biotech turnaround, with revenue surging from $17 million in 2016 to nearly $1 billion in 2024, driven by the successful launches of Nuplazid for Parkinson’s psychosis and Daybue for Rett syndrome. This growth has delivered blockbuster potential, sky-high per-employee revenue efficiency ($1.46 million), robust gross margins above 91%, and a pivotal shift to profitability—net income flipping to $226 million in 2024 alongside positive free cash flow of $157 million. A fortress balance sheet, with $756 million in net cash and negligible debt, underpins this momentum, stabilizing shares outstanding and compressing valuations to reasonable levels like 3.2x price-to-sales.

Yet caution prevails amid historical deep losses, stock volatility tied to drug milestones, and recent insider selling totaling $2.6 million with zero buys, signaling potential peak optimism. Downside risks from Daybue’s safety scrutiny, payer pushback, emerging competition, and execution hurdles loom large in a sector prone to missteps, especially with erratic past ROIC and macro pressures like rate hikes compressing multiples.

Analysts project continued expansion—2027 revenue at $1.33 billion and EPS near $1—implying up to 82% upside, but the base case feels optimistic given front-loaded growth and patent cliffs ahead. Fairly priced today, Acadia merits monitoring for FCF consistency and insider conviction before commitment, with Q1 2026 Daybue data as a key watchpoint.

Read full commentary →

ACADIA Pharmaceuticals Inc. (ACAD) Latest News

News by impact score

Fine-tune

24 Aug

4 , 10:04 AM
Acadia Pharmaceuticals receives European Commission approval for Daybue in Rett Syndrome. European approval expands market access for Daybue in Rett Syndrome treatment.

4 , 3:01 AM
European Commission approves DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett Syndrome in the European Union. EU approval of DAYBU opens major new market for ACADIA's Rett Syndrome treatment.

12 Aug

4 www.marketbeat.com, 3:04 PM
ACADIA Pharmaceuticals expands DAYBUE and NUPLAZID reach ahead of key Alzheimer’s data. Product expansions ahead of pivotal Alzheimer’s data are positioned to significantly shift ACADIA market trajectory.

11 Aug

4 transcript www.fool.com, 11:02 PM
Acadia Pharmaceuticals (ACAD) Q2 2026 earnings call transcript covers quarterly financial results, operational updates, and forward guidance. Earnings transcripts disclose results and guidance that often shift investor views and valuation.

10 Aug

3 , 11:33 AM
Morgan Stanley projects Acadia Pharmaceuticals gains from Daybue and Nuplazid growth while noting RADIANT data adds risk to the outlook. Product growth forecasts offset by clinical data risks point to moderate effects on ACAD trajectory and sentiment.

7 Aug

3 , 3:09 PM
Analysts raised fair value for Acadia Pharmaceuticals stock citing expected Daybue growth. Analyst fair value increase tied to Daybue growth outlook can lift near-term stock sentiment and valuation.

6 Aug

3 , 12:20 PM
Rising earnings estimates for Acadia Pharmaceuticals Inc. (ACAD) may push the stock price higher. Rising earnings estimates can moderately affect ACAD stock performance and investor views without major strategic shifts.

5 Aug

4 , 11:44 AM
ACAD beat Q2 earnings and revenue estimates while raising its 2026 guidance on strong product sales. Earnings beat combined with raised long-term outlook directly improves ACAD financial trajectory and market sentiment.

4 , 1:06 AM
ACADIA Pharmaceuticals Inc (ACAD) reported strong revenue growth during its Q2 2026 earnings call. Strong revenue growth in earnings highlights signals major positive shift in financial trajectory and investor outlook.

4 Aug

3 www.marketbeat.com, 6:03 PM
ACADIA Pharmaceuticals reported Q2 results and pipeline updates during its earnings call, covering financial performance, product developments, and strategic outlook for the period. Quarterly earnings and pipeline details typically influence near-term stock movement and sentiment without guaranteeing long-term trajectory shifts.

3 , 4:05 PM
Acadia Pharmaceuticals reported its second quarter 2026 financial results. Quarterly financial results provide key insights into operational performance and outlook.

30 Jul

3 , 8:09 AM
ACAD stock appears undervalued against fair value despite clinical risks in its pipeline. Valuation below fair value points to potential upside for ACAD shares while clinical risks may limit broader market shifts.

28 Jul

3 , 10:00 AM
Acadia Pharmaceuticals (ACAD) is projected to surpass earnings estimates, leading to questions over whether investors should purchase the stock. Expected earnings outperformance may moderately shift near-term investor sentiment and valuation for ACAD without altering long-term trajectory.

21 Jul

4 , 10:47 AM
ACADIA Pharmaceuticals receives FDA Fast Track designation for its Alzheimer's disease candidate. FDA Fast Track status speeds ACAD Alzheimer's candidate development and approval path.

20 Jul

4 , 9:05 AM
Acadia Pharmaceuticals Inc. (ACAD) receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis. FDA Fast Track Designation accelerates regulatory review for Remlifanserin, potentially speeding market entry and boosting ACAD valuation.

10 Jul

4 , 10:15 AM
Daybue success leaves ACADIA Pharmaceuticals potentially still undervalued with upside remaining in its valuation. Daybue launch creates major new revenue stream and shifts ACAD trajectory and investor sentiment.

4 , 9:12 AM
CHMP issued positive ruling on DAYBUE for Rett Syndrome, enabling potential European approval and commercialization that expands ACADIA Pharmaceuticals market access and supports revenue growth. Positive CHMP ruling on DAYBUE opens European market for ACADIA's lead asset and materially lifts long-term revenue outlook.

29 Jun

4 , 11:15 AM
ACADIA Pharmaceuticals stock rises after CHMP issues positive opinion backing Daybue for EU approval to treat Rett Syndrome. CHMP positive opinion advances Daybue toward EU approval and opens new revenue stream in Rett Syndrome.

26 Jun

4 www.fool.com, 12:37 PM
Acadia Pharmaceuticals stock rises sharply today on positive developments. Sharp stock gains reflect major positive events likely to alter investor sentiment and company trajectory.

4 stocktwits.com, 12:30 PM
ACADIA Pharmaceuticals stock eyes its best day in over a year after CHMP recommended European approval of its drug for a rare nerve disorder. CHMP positive opinion on European approval for rare disease drug directly lifts ACAD revenue outlook and share price trajectory.

4 , 6:49 AM
ACADIA Pharmaceuticals receives CHMP recommendation for EU approval of DAYBU® (trofinetide). CHMP positive opinion for trofinetide approval opens major new EU market for ACADIA's lead product.

4 www.biopharmadive.com, 5:24 AM
Acadia Pharmaceuticals secured European regulatory approval for its drug on the second submission attempt. European approval opens a major new market and drives revenue growth for Acadia.

19 May

4 www.marketbeat.com, 10:14 AM
ACADIA Pharmaceuticals highlights its Alzheimer’s psychosis pipeline progress alongside continued growth for NUPLAZID and DAYBUE. Pipeline updates and product growth directly support higher future revenue and investor sentiment for ACAD.

12 May

4 www.marketbeat.com, 8:25 PM
ACADIA Pharmaceuticals Inc. (ACAD) targets a $1 billion brand opportunity in neuropsychiatry as key clinical data looms, positioning the company for potential blockbuster growth amid upcoming readouts. Pursuit of $1B neuropsychiatry brand with imminent key data represents major strategic expansion poised to significantly enhance revenue trajectory and investor sentiment.

11 May

4 Simply Wall St., 7:27 AM
ACADIA Pharmaceuticals Inc. (ACAD) missed EPS estimates by 58%, causing analysts to revise forecasts downward amid concerns over future performance. A 58% EPS miss prompts analyst forecast cuts, significantly impacting investor sentiment and ACAD's stock trajectory.

8 May

4 Simply Wall St., 11:17 PM
ACADIA Pharmaceuticals Inc. (ACAD) missed earnings expectations, suffered an EU regulatory setback, and announced an R&D transition, signaling challenges ahead for shareholders and the company's growth trajectory. Earnings miss, EU setback, and R&D transition represent major hurdles to financial performance, international expansion, and pipeline development.

7 May

3 Zacks, 11:42 AM
ACADIA Pharmaceuticals Inc. (ACAD) Q1 earnings and revenues missed analyst estimates despite year-over-year sales growth. Q1 earnings and revenue misses despite Y/Y sales growth moderately affect financial performance and investor sentiment.

6 May

4 www.marketbeat.com, 6:57 PM
ACADIA Pharmaceuticals released Q1 earnings call highlights detailing financial results, pipeline progress, and strategic updates. Q1 earnings highlights signal significant financial performance and operational advancements shaping ACADIA's future trajectory.

4 transcript www.fool.com, 6:46 PM
Acadia Pharmaceuticals (ACAD) Q1 2026 earnings call transcript details quarterly financial results, revenue from key drugs like Daybue and Nuplazid, R&D updates, and forward guidance amid competitive CNS market pressures. Q1 2026 earnings transcript covers financial performance, product sales, and guidance directly influencing ACAD's stock trajectory and investor sentiment.

3 Zacks, 5:25 PM
Acadia Pharmaceuticals (ACAD) reported Q1 earnings of $0.06 per share, missing the $0.19 consensus estimate, with revenue of $198.6 million falling short of the $212.9 million expected. Missing Q1 earnings and revenue estimates highlights weaker financial performance, moderately impacting investor sentiment and stock price.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us